Human hematopoietic stem and progenitor cell antigen and methods for its use
OwnerAmy H. Yin, Sheri Miraglia +2inventors
InventorsAmy H. Yin, Sheri Miraglia, Wayne G. Godfrey, David W. Buck
Life of this patent
Estimating the term…
Loading patent…
OwnerAmy H. Yin, Sheri Miraglia +2inventors
InventorsAmy H. Yin, Sheri Miraglia, Wayne G. Godfrey, David W. Buck
Estimating the term…
A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
An antibody that specifically binds to AC133 antigen.
A method for enrichment of hematopoietic stem or progenitor cells or both, said method comprising:
A substantially pure population of hematopoietic progenitor cells, wherein said cells are bound to a reagent that specifically binds to the hematopoietic progenitor cell antigen recognized by the antibody produced by the hybridoma cell line ATCC HB12346.
An isolated nucleic acid molecule, wherein said molecule comprises:
An isolated polypeptide, wherein said polypeptide comprises:
An isolated polypeptide, wherein said polypeptide comprises the amino acid sequence from extracellular N-terminus, aa 20-107;
In a method of isolating hematopoietic stem cells using a cell separation technique based on identification of stem cells by selective binding of a ligand to an antigenic marker on said stem cell, an improvement which comprises:
A reagent that bind specifically to AC133 antigen with less than 5% crossreactivity with any antigen present on mature blood cells.
Dependencies are inferred from the claim text.